In a research report issued today, Roth Capital analyst Scott Henry downgrades shares of Salix Pharmaceuticals (NASDAQ:SLXP) from Buy to Hold and reduced his price …
In a research report released today, Brean Capital analyst Jonathan Aschoff reaffirmed a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a price target …
In a research report issued today, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a $184 price target, following today’s …
Back on July 3rd of this year, I wrote about a good find in pharma called Salix Pharmaceuticals (NASDAQ:SLXP). Salix Pharmaceuticals is a …
In a research report published today, Cantor Fitzgerald analyst Irina Rivkind reiterated her Buy rating on Salix Pharma (NASDAQ:SLXP) and increased her price …
In a research report published today, Roth Capital analyst Scott Henry maintained a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a $160 price …
In a research report issued yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (SLXP) with a $157 price target, following a …
In a research report released yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals Ltd. (SLXP) with a $157 …
In a research note released today, Canaccord analyst Corey Davis reiterated coverage with a Buy rating on shares of Salix Pharmaceuticals (SLXP) and a $161.00 price target, following yesterday’s news of a definitive merger agreement …
In a research note released Tuesday, Roth Capital analyst Scott Henry maintained a Buy rating on Salix Pharmaceuticals (SLXP), and a 12 month price target of $130/share, following today’s news that SLXP’s Xifaxan …
